Evidence map›Paper›PMID 23413027›Full record

ArticleThe Journal of biological chemistry2013

The rare TXNRD1_v3 ("v3") splice variant of human thioredoxin reductase 1 protein is targeted to membrane rafts by N-acylation and induces filopodia independently of its redox active site integrity.

Marcus Cebula, Naazneen Moolla, Alexio Capovilla, Elias S J Arnér

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. SLC15A4 mediates M1-prone metabolic shifts in macrophages and guards immune cells from metabolic stress.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Ferroptosis-Related Flavoproteins: Their Function and Stability.International journal of molecular sciences · 2021
    Review
  8. Effects of Mammalian Thioredoxin Reductase Inhibitors.Handbook of experimental pharmacology · 2021
    Article
  9. Selenoproteins in colon cancer.Free radical biology & medicine · 2018
    Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Marcus CebulaDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Naazneen MoollaDepartment of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, 2193 Johannesburg, South Africa.
Alexio CapovillaDepartment of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, 2193 Johannesburg, South Africa.
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Electronic address: Elias.Arner@ki.se.
Karolinska Institutet · SEUniversity of the Witwatersrand · ZA

Funding

Medical Research Council
6 · The paper itself

Abstract

The human selenoprotein thioredoxin reductase 1 (TrxR1), encoded by the TXNRD1 gene, is a key player in redox regulation. Alternative splicing generates several TrxR1 variants, one of which is v3 that carries an atypical N-terminal glutaredoxin domain. When overexpressed, v3 associates with membranes and triggers formation of filopodia. Here we found that membrane targeting of v3 is mediated by myristoylation and palmitoylation of its N-terminal MGC motif, through which v3 specifically targets membrane rafts. This was suggested by its localization in cholera toxin subunit B-stained membrane areas and also shown using lipid fractionation experiments. Utilizing site-directed mutant variants, we also found that v3-mediated generation of filopodia is independent of the Cys residues in its redox active site, but dependent upon its membrane raft targeting. These results identify v3 as an intricately regulated protein that expands TXNRD1-derived protein functions to the membrane raft compartment.

Indexed as

Alternative SplicingOxidation-ReductionAcylationAmino Acid MotifsAmino Acid SequenceCatalytic DomainCell Line, TumorCysteineGlutaredoxinsGreen Fluorescent ProteinsHEK293 CellsHumansLipidsMembrane MicrodomainsMolecular Sequence DataMutationCysteineGlutaredoxinsGreen Fluorescent ProteinsLipidsRecombinant Fusion ProteinsThioredoxin Reductase 1TXNRD1 protein, human

Identifiers

PMID23413027
PMCPMC3617239
OpenAlexW2151079177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.